TP53 deletion is associated with poor survival of adult ALK-positive ALCL patients receiving CHOP-based chemotherapy.

ABSTRACT: In most cases of anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK + ALCL), long-term survival is achieved using CHOP therapy. However, some cases have a poor prognosis. Here, we investigated the clinical impact of TP53 deletion on adult ALK + ALCL patients via a multicenter, retrospective analysis. TP53 deletion was evaluated by fluorescence in situ hybridization (FISH) using paraffin sections of lymphoma samples. To re-evaluate the FISH results, whole genome copy number changes were analyzed in DNA extracted from paraffin sections using OncoScan analysis. Fourteen patients treated with first-line chemotherapy enrolled at six centers were analyzed. All patients received CHOP-based therapy as initial therapy. The 5-year progression-free survival (PFS) and overall surv

SUBMITTER: Katagiri S 

PROVIDER: S-EPMC12031747 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature